碧迪医疗2025财年业绩超预期，股价波动显著

Core Viewpoint - Becton Dickinson reported a revenue of $5.89 billion for Q4 FY2025, an 8% year-over-year increase, with adjusted earnings per share of $3.96 exceeding expectations; the total annual revenue reached $21.84 billion, up 8.2% [1] Group 1: Financial Performance - Q4 FY2025 revenue was $5.89 billion, reflecting an 8% year-over-year growth [1] - Adjusted earnings per share for Q4 were $3.96, surpassing market expectations [1] - Total revenue for the fiscal year 2025 was $21.84 billion, marking an 8.2% increase compared to the previous year [1] Group 2: Institutional Perspectives - Citigroup maintained a "Buy" rating with a target price of $232 [2] - TD Cowen raised its target price to $189 while maintaining a "Hold" rating [2] - Other institutions, including Barclays, have also adjusted their target prices, focusing on the company's strategy post-business divestiture [2] Group 3: Stock Performance - The stock experienced significant volatility over the past week, with a cumulative increase of 9.87% and a fluctuation range of 15.58% [3] - On February 11, the closing price was $180.62, with a single-day increase of 5.21% [3] - On February 12, the stock closed at $178.32, reflecting a decrease of 1.27% [3] - Trading activity was robust, with a transaction volume of $1.065 billion on February 11 [3] Group 4: Recent Events - The launch of a Chinese international medical equipment and device trading platform is expected to enhance global expectations for the sector [4] - Waters Corporation completed a merger related to Becton Dickinson's business, resulting in the establishment of four new divisions focused on life sciences and diagnostics [4]